Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).

7-Ethyl-10-hydroxycamptothecin (SN-38) is the pharmacologically active metabolite of irinotecan, in addition to being responsible for severe toxicity. Glucuronidation is the main metabolic pathway of SN-38 and has been shown to protect against irinotecan-induced gastrointestinal toxicity. The purpose of this study was to determine whether common polymorphic UDP-glucuronosyltransferase (UGT) affects SN-38 glucuronidation. First, kinetic characterization of SN-38-glucuronide (SN-38-G) formation was assessed for all known human UGT1A and UGT2B overexpressed in human embryonic kidney 293 cells. To assess the relative activity of UGT isoenzymes for SN-38, rates of formation of SN-38-G were monitored by liquid chromatography/mass spectrometry analysis and normalized by level of UGT cellular expression. Determination of intrinsic clearances predicts that hepatic UGT1A1 and UGT1A9 and the extrahepatic UGT1A7 are major components in SN-38-G formation, whereas a minor role is suggested for UGT1A6, UGT1A8, and UGT1A10. In support of the involvement of UGT1A9, a strong coefficient of correlation was observed in the glucuronidation of SN-38 and a substrate, mainly glucuronidate, by UGT1A9 (flavopiridol) by human liver microsomes (coefficient of correlation, 0.905; p = 0.002). In vitro functional experiments revealed a negative impact of the UGT1A1 allelic variants. Residual activities of 49, 7, 8, and 11% were observed for UGT1A1*6 (G(71)R), UGT1A1*27 (P(229)Q), UGT1A1*35 (L(233)R), and UGT1A1*7 (Y(486)D), respectively. Common variants of UGT1A7, UGT1A7*3 (N(129)K;R(131)K;W(208)R), and UGT1A7*4 (W(208)R), displayed residual activities of 41 and 28% compared with the UGT1A7*1 allele. Taken together, these data provide the evidence that molecular determinants of irinotecan response may include the UGT1A polymorphisms studied herein and common genetic variants of the hepatic UGT1A9 isoenzyme yet to be described.

[1]  D. Greenblatt,et al.  Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. , 2001, The Journal of pharmacology and experimental therapeutics.

[2]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[3]  N. Munshi,et al.  Arsenic trioxide: an emerging therapy for multiple myeloma. , 2001, The oncologist.

[4]  M. Ratain,et al.  Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J Verweij,et al.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  D. Hum,et al.  Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. , 2000, Journal of molecular biology.

[7]  M. Ciotti,et al.  Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. , 1997, Pharmacogenetics.

[8]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[9]  D. Hum,et al.  Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. , 2001, Endocrinology.

[10]  D. Hum,et al.  The Monkey and Human Uridine Diphosphate-Glucuronosyltransferase UGT1A9, Expressed in Steroid Target Tissues, Are Estrogen-Conjugating Enzymes. , 1999, Endocrinology.

[11]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[12]  M. Rothenberg.  Efficacy and toxicity of irinotecan in patients with colorectal cancer. , 1998, Seminars in oncology.

[13]  A. Bélanger,et al.  Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. , 2001, Biochemistry.

[14]  L. Iyer.  Inherited variations in drug-metabolizing enzymes: significance in clinical oncology. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[15]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[16]  S. Yasumura,et al.  Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese , 1999, Journal of Human Genetics.

[17]  F. Lokiec,et al.  Irinotecan (CPT-11) metabolites in human bile and urine. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Matthew W. Pennington,et al.  Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. , 2001, Pharmacogenetics.

[19]  C. Guillemette,et al.  Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. , 1997, Endocrinology.

[20]  M. Guida,et al.  Genomic organization of the UGT2b gene cluster on human chromosome 4q13. , 2000, Pharmacogenetics.

[21]  E. Van Cutsem,et al.  Optimizing the use of irinotecan in colorectal cancer. , 2001, The oncologist.

[22]  H. Saka,et al.  UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  C. Guillemette,et al.  In Vitro Characterization of Hepatic Flavopiridol Metabolism Using Human Liver Microsomes and Recombinant UGT Enzymes , 2002, Pharmaceutical Research.

[24]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[25]  M. Ciotti,et al.  Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. , 1999, Biochemical and biophysical research communications.

[26]  M. Ratain.  Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[28]  L. Saltz,et al.  Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. , 2001, The oncologist.

[29]  S. Wrighton,et al.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[30]  C. Guillemette,et al.  Differential Regulation of Two Uridine Diphospho-Glucuronosyltransferases, UGT2B15 and UGT2B17, in Human Prostate LNCaP Cells. , 1997, Endocrinology.

[31]  K. Hayasaka,et al.  Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate‐glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese , 1998, Biochemistry and molecular biology international.

[32]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[33]  E. Sausville,et al.  In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[34]  M. Iigo,et al.  Relationship between Development of Diarrhea and the Concentration of SN‐38, an Active Metabolite of CPT‐11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT‐11 , 1993, Japanese journal of cancer research : Gann.

[35]  M. Rothenberg.  Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond. , 2001, The oncologist.

[36]  J. Robert,et al.  Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. , 1994, Journal of chromatography. B, Biomedical applications.

[37]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[38]  M. Manns,et al.  Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. , 2001, Gastroenterology.

[39]  A Messori,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[40]  C. Guillemette,et al.  Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. , 2000, Pharmacogenetics.

[41]  H. Keino,et al.  Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. , 1993, Biochemical and biophysical research communications.

[42]  M. Fukuoka,et al.  Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin , 1995, Japanese journal of cancer research : Gann.